Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon
"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
Fierce Pharma
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
pharmaphorum
J&J adds first new indication for Caplyta since takeover
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
BioPharma Dive
J&J brain drug acquired in $14.6B buyout cleared for broader use
Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...